M

MacroGenics

D

MGNX

USD

0.085

(2.5758%)

Market Closed

15,639.00

حجم التداول

-1.72

الربح لكل سهم

-

العائد الربحي

-1.545662

P/E

212,314,795.94

حجم السوق

اليوم

2.5758%

1 اسبوع

-6.233%

1 شهر

-4.916%

6 اشهر

-78.273%

12 اشهر

-26.253%

بداية السنة

-64.813%

كل الوقت

0%

أصول ذات صلة

Title:
MacroGenics

Sector:

Healthcare

Industry:

Biotechnology

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 CTLA-4), Tebotelimab (PD-1 LAG-3), MGD024 (CD123 CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV CD3).

هل تحتاج مساعدة او لديك استفسار؟

تواصل معنا